Pancreatic | Interview with Andrew H Ko, MD


Manage episode 229273556 series 1464173
By Dr Neil Love. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Pancreatic Cancer Update – Part 1: Our interview with Dr. Ko highlights the following topics as well as cases from his practice:

  • Case: A 45-year-old woman with borderline resectable adenocarcinoma of the pancreas attains an excellent response to neoadjuvant FOLFIRINOX: 0m0s
  • Role of genetic counseling and molecular profiling for patients with pancreatic cancer: 1m42s
  • Effects of mutational load and PD-L1 expression on response to immunotherapy: 4m34s
  • Pathophysiology of pancreatic cancer: 5m43s
  • Radiographic criteria for defining resectable versus borderline resectable disease and implications for therapy: 8m3s
  • Response and tolerability with neoadjuvant FOLFIRINOX: 12m14s
  • Ongoing Phase II SWOG-S1505 trial of perioperative modified FOLFIRINOX (mFOLFIRINOX) versus gemcitabine/nab paclitaxel for resectable adenocarcinoma of the pancreas: 17m22s
  • Efficacy of neoadjuvant chemotherapy for patients with resectable pancreatic cancer: 20m6s
  • Case: A 78-year-old man with resected pancreatic cancer treated with adjuvant single-agent gemcitabine: 24m56s
  • Risk of recurrence for patients with resectable pancreatic cancer: 28m31s
  • Results from the Phase III PRODIGE 24/CCTG PA.6 trial evaluating adjuvant mFOLFIRINOX versus gemcitabine for patients with resected pancreatic ductal adenocarcinoma: 32m25s
  • Risks and benefits with nab paclitaxel/gemcitabine and FOLFIRINOX as adjuvant therapy: 33m49s
  • Case: A 70-year-old man with metastatic adenocarcinoma of the pancreas develops severe peripheral neuropathy with gemcitabine/nab paclitaxel as first-line therapy: 37m13s
  • Peripheral neuropathy associated with nab paclitaxel: 39m40s
  • Approach to first-line therapy for metastatic pancreatic cancer: 41m40s
  • Combination immunotherapeutic approaches under investigation for advanced pancreatic cancer: 45m25s
  • Efficacy and tolerability of the pegylated recombinant human hyaluronidase enzyme PEGPH20 in patients with advanced pancreatic cancer: 47m14s
  • Therapeutic options for patients with metastatic pancreatic cancer and disease progression on gemcitabine/nab paclitaxel: 51m25s
  • NAPOLI-1: Results of a Phase III trial of nanoliposomal irinotecan (nal-IRI) and 5-FU/leucovorin (LV) for metastatic pancreatic cancer after gemcitabine-based therapy: 57m15s
  • Palliative care for patients with metastatic pancreatic cancer: 1h0m15s
  • Case: A 54-year-old woman with locally advanced pancreatic cancer and refractory ascites: 1h4m45s
  • Case: A 53-year-old man of Ashkenazi Jewish descent with a strong family history of BRCA mutation-associated cancers presents with metastatic pancreatic cancer and is found to harbor a germline BRCA2 mutation: 1h8m44s
  • Case: A 62-year-old woman with pancreatic cancer and a solitary liver lesion receives FOLFIRINOX followed by stereotactic body radiation therapy: 1h12m55s

Select publications

2183 episodes